GlassScriptPhysician profile
Josh Minga
NPI 1184080640
$1,191.58
in general payments reported to CMS, 2019-2025
19 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.43 · 2022: $34.68 · 2023: $166 · 2024: $570 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $492.40 | 2024-2025 | Inspire |
| Grifols USA, LLC | $190.15 | 2022-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $94.64 | 2023-2025 | Glassia |
| Medtronic, INC. | $65.81 | 2023-2024 | Stealthstation S8 Platform, Intellis Adaptivestim, Arcpoint |
| Mylan Specialty L.P. | $51.02 | 2024 | Yupelri |
| Philips North America LLC | $40.99 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Csl Behring | $26.23 | 2023 | Kcentra |
| Alexion Pharmaceuticals, INC. | $26.07 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $25.66 | 2025 | Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $20.93 | 2023 | |
| Pfizer INC. | $19.91 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2021 | |
| Si-Bone, INC. | $18.71 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.04 | 2023 | Gliadel |
| Merz Pharmaceuticals, LLC | $17.68 | 2025 | Xeomin |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $17.63 | 2024 | Daxxify |
| Abbvie INC. | $17.55 | 2024 | |
| Nevro Corp. | $15.06 | 2024 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.67 | 2023 | Spiriva Respimat, Stiolto Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josh Minga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.